Cannabis as Medicine

EDMONTON and VANCOUVER, March 13, 2018 Aurora Cannabis Inc. and PreveCeutical Medical Inc. today announced the grant of three permits by the Australian Government, Department of Health, for the importation of cannabis into Australia for research purposes (the “Permits”). The Permits were granted to the Pharmacy Australia Centre of Excellence (“PACE”) at the University of Queensland (“UQ”) and allow PACE to import shipments

Summary Research is expanding for the use of cannabidiol as an anticonvulsant drug. The mechanism of cannabidiol in paediatric epilepsy is unclear but is thought to play a role in modulation of synaptic transmission. Evidence for its efficacy in treating epilepsy is limited but growing, with a single pharmaceutical company-funded randomised double-blind controlled trial in

Roger Ladouceur – Canadian Family Physician February 2018 “The evidence indicates the most consistent effects of medical cannabinoids are adverse events. A variety of adverse events have a greater magnitude of effect than the potential benefits for the conditions targeted.1 The conclusions drawn by this analysis are not surprising. Study after study, analysis after analysis, and

New medical guidelines have been issued in Canada, where cannabis is legal They warn the effects of the drug outweigh minor benefits for most conditions  And for some, it states it most often is only marginally better than a placebo  The new document will be distributed to 30,000 doctors in Canada New medical guidelines issued

By Ariana Eunjung Cha January 24  A new class of epilepsy medications based on an ingredient derived from marijuana could be available as soon as the second half of 2018 in the United States, pending Food and Drug Administration approval. Officials from GW Pharmaceuticals, the company that developed the drug, on Wednesday announced promising results from a study on 171 patients randomized into

Abstract Cryptococcal meningitis is a life-threatening condition most commonly observed in immunocompromised individuals. We describe a daily cannabis smoker without evidence of immunodeficiency presenting with confirmed Cryptococcus neoformans meningitis. An investigation of cannabis samples from the patient’s preferred dispensary demonstrated contamination with several varieties of Cryptococcus, including C. neoformans, and other opportunistic fungi. These findings raise concern regarding the

This review provides an overview of the changing US epidemiology of cannabis use and associated problems. Adults and adolescents increasingly view cannabis as harmless, and some can use cannabis without harm. However, potential problems include harms from prenatal exposure and unintentional childhood exposure; decline in educational or occupational functioning after early adolescent use, and in

Conclusion: Medical marijuana laws appear to have contributed to increased prevalence of illicit cannabis use and cannabis use disorders. State-specific policy changes may also have played a role. While medical marijuana may help some, cannabis-related health consequences associated with changes in state marijuana laws should receive consideration by health care professionals and the public. View

The World Health Organisation has announced its findings after a months-long study into cannabidiol, or CBD, declaring the medicinal cannabis component to be well tolerated and an effective treatment for some forms of epilepsy. The WHO also recommended CBD not be a scheduled drug. According to the report, the non-psychoactive component of cannabis does not exhibit any

By Carter Sherman Nov 8, 2017 Cannabidiol, a major component of marijuana, is in high demand these days for its purported health benefits. But a study published on Tuesday discovered that people trying to treat themselves with cannabidiol products likely aren’t getting what they’re paying for. The study, led by the University of Pennsylvania, tested 84 cannabidiol products purchased